Caveolin-1 as a promoter of tumour spreading: When, how, where and why

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 3, 2013, Pages 325-336

  Senetta, Rebecca ^a   Stella, Giulia ^b   Pozzi, Ernesto ^c   Sturli, Niccolo ^d   Massi, Daniela ^d   Cassoni, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biomarkers; Cancer; Caveolin 1; Metastases; Targeted therapy

Indexed keywords

CAVEOLIN 1;

ANIMAL; ARTICLE; CELL TRANSFORMATION; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CAVEOLIN 1; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84875782610     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12030     Document Type: Article

References (132)

1. Mercier I, Jasmin JF, Pavlides S, et al. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest. 2009; 89: 614-23.
2. Burgermeister E, Liscovitch M, Röcken C, et al. Caveats of caveolin-1 in cancer progression. Cancer Lett. 2008; 268: 187-201.
3. Goetz JG, Lajoie P, Wiseman SM, et al. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008; 27: 715-35.
4. Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer. 2003; 3: 571-81.
5. Sinha B, Koster D, Ruez R, et al. Cells respond to mechanical stress by rapid disassembly of caveolae. Cell. 2010; 144: 402-13.
6. Lisanti MP, Scherer PE, Tang Z, et al. Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol. 1994; 4: 231-5.
7. Hill MM, Bastiani M, Luetterforst R, et al. PTFR-Cavin, a conserved cytoplasmatic protein required for caveola formation and function. Cell. 2008; 132: 113-24.
8. McMahon KA, Zajicek H, Li WP, et al. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J. 2009; 28: 1001-15.
9. Hansen CG, Bright NA, Howard G, et al. SDPR induces membrane curvature and functions in the formation of caveolae. Nat Cell Biol. 2009; 11: 807-14.
10. Hill MM, Daud NH, Aung CS, et al. Co-regulation of cell polarization and migration by caveolar proteins PTRF/cavin-1 and caveolin-1. PLoS ONE. 2012; 7: e43041.
11. Rothberg KG, Heuser JE, Donzell WC, et al. Caveolin, a protein component of caveolae membrane coats. Cell. 1992; 68: 673-82.
12. Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 1998; 436: 403-10.
13. Li S, Seitz R, Lisanti MP. Phosphorylation of caveolin by src tyrosine kinases. The alfa isoformof caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem. 1996; 271: 3863-8.
14. Glenney JR. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem. 1989; 264: 20163-6.
15. Hayer A, Stoeber M, Ritz D, et al. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol. 2010; 191: 615-29.
16. Joshi B, Bastiani M, Strugnell SS, et al. Phosphocaveolin-1 is a mechanotransducer that induces caveola biogenesis via Egr1 transcriptional regulation. J Cell Biol. 2012; 199: 425-35.
17. Sáinz-Jaspeado M, Martin-Liberal J, Lagares-Tena L, et al. Caveolin-1 in sarcomas: friend or foe? Oncotarget. 2011; 2(4): 305-12.
18. Kim EJ, Sohn JH, Kim MK, et al. The loss of expression of caveolin-1 in gastrointestinal stromal tumors. Korean J Pathol. 2005; 39: 338-44.
19. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001; 159: 1635-43.
20. Cerezo A, Guadamillas MC, Goetz JG, et al. The absence of caveolin-1 increases proliferation and anchorage- independent growth by a Rac-dependent, Erk-independent mechanism. Mol Cell Biol. 2009; 29: 5046-59.
21. Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 2001; 61: 2361-4.
22. Lee H, Park DS, Razani B, et al. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol. 2002; 161: 1357-69.
23. Li T, Sotgia F, Vuolo MA, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol. 2006; 168: 1998-2013.
24. Bonuccelli G, Casimiro MC, Sotgia F, et al. Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol. 2009; 174: 1650-62.
25. Rieth MD, Lee J, Glover KJ. Probing the caveolin-1 P132L mutant: critical insights into its oligomeric behavior and structure. Biochemistry. 2012; 51: 3911-8.
26. Patani N, Lambros MB, Natrajan R, et al. Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat. 2012; 131: 307-10.
27. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007; 13: 90-101.
28. Karam JA, Lotan Y, Roehrborn CG, et al. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007; 67: 614-22.
29. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 2003; 89: 1909-13.
30. Thomas S, Overdevest JB, Nitz MD, et al. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 2011; 71: 832-41.
31. Cassoni P, Senetta R, Castellano I, et al. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol. 2007; 31: 760-9.
32. Senetta R, Trevisan E, Rudà R, et al. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol. 2009; 68: 425-31.
33. Senetta R, Miracco C, Lanzafame S, et al. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro Oncol. 2011; 13: 176-83.
34. Waalkes S, Eggers H, Blasig H, et al. Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer. Biomark Med. 2011; 5: 219-25.
35. Yang G, Truong LD, Wheeler TM, et al. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999; 59: 5719-23.
36. Satoh T, Yang G, Egawa S, et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer. 2003; 97: 1225-33.
37. Cassoni P, Daniele L, Maldi E, et al. Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology. 2009; 55: 20-7.
38. Felicetti F, Parolini I, Bottero L, et al. Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer. 2009; 125: 1514-22.
39. Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004; 64: 4277-85.
40. Joo HJ, Oh DK, Kim YS, et al. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2004; 93: 291-6.
41. Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer. 2002; 94: 929-33.
42. Ho CC, Huang PH, Huang HY, et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 2002; 161: 1647-56.
43. Chen HL, Fan LF, Gao J, et al. Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma. Oncol Rep. 2011; 25: 359-66.
44. Yeh D, Chen C, Sun MZ, et al. Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446 cell. Anat Rec. 2009; 292: 1584-92.
45. Zhan P, Shen XK, Qian Q, et al. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas. Oncol Rep. 2012; 27: 1072-8.
46. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998; 4: 1873-80.
47. Sáinz-Jaspeado M, Lagares-Tena L, Lasheras J, et al. Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize. Mol Cancer Res. 2010; 8: 1489-500.
48. Tse EY, Ko FC, Tung EK, et al. Caveolin-1 overexpression is associated with hepatocellular carcinoma tumorigenesis and metastasis. J Pathol. 2012; 226: 645-53.
49. Cokakli M, Erdal E, Nart D, et al. Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer. 2009; 9: 65.
50. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol. 2008; 84: 177-89.
51. Lacroix-Triki M, Geyer FC, Reis-Filho JS. Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced. J Mol Diagn. 2010; 12: 562-5.
52. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789-99.
53. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet. 2005; 15: 87-96.
54. Arnold A, Papanicolau A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005; 23: 4215-24.
55. Pancotti F, Roncuzzi L, Maggiolini M, et al. Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal. 2012; 24: 1390-7.
56. Bromberg JF. Stat proteins and oncogenesis. J Clin Invest. 2002; 109: 1139-42.
57. Chiu WT, Lee HT, Huang FJ, et al. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res. 2011; 71: 4932-43.
58. Park HJ, Gusarova G, Wang Z, et al. Deregulation of FoxM1b leads to tumor metastasis. EMBO Mol Med. 2011; 3: 21-34.
59. Huang C, Qiu Z, Wang L, et al. A novel FoxM1-Caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 2012; 72: 655-65.
60. Lee H, Volonte D, Galbiati F, et al. Constitutive and growth factor-regulated phosphorylation of cav-1 occurs at the same site (Tyr-14) in vivo: identification of a c-src/Cav-1/Grb7 signaling cassette. Molec Endocrinology. 2000; 14: 1750-75.
61. Kim YN, Wiepz GJ, Guadarrama AG, et al. Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin 1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. J Biol Chem. 2000; 275: 7481-91.
62. Mastick CC, Brady MJ, Saltiel AR. Insulin stimulates the tyrosine phosphorylation of caveolin. J Cell Biol. 1995; 129: 1523-31.
63. Kimura A, Mora S, Shigematsu S, et al. The insulin receptor catalyizes the tyrosine phosphorylation of caveolin-1. J Biol Chem. 2002; 277: 30153-8.
64. Hall A. Rho-GTP ases and the actin cytoskeleton. Science. 1998; 279: 509-14.
65. Stahlhut M, van Deurs B. Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol Biol Cell. 2000; 11: 325-37.
66. Grande-García A, Echarri A, de Rooij J, et al. Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. J Cell Biol. 2007; 177: 683-94.
67. Wary KK, Mariotti A, Zurzolo C, et al. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998; 94: 625-34.
68. Wei Y, Yang X, Liu Q, et al. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999; 144: 1285-94.
69. Joshi B, Strugnell SS, Goetz JG, et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 2008; 68: 8210-20.
70. Arpaia E, Blaser H, Quintela-Fandino M, et al. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 2012; 31: 884-96.
71. Goetz JG, Joshi B, Lajoie P, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol. 2008; 180: 1261-75.
72. Cosset EC, Godet J, Entz-Werlé N, et al. Involvement of the TGFβ pathway in the regulation of α(5) β(1) integrins by caveolin-1 in human glioblastoma. Int J Cancer. 2012; 131: 601-11.
73. Martin S, Cosset EC, Terrand J, et al. Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. Biochim Biophys Acta. 2009; 1793: 354-67.
74. Burridge K, Fath K. Focal contacts: transmembrane links between the extracellular matrix and the cytoskeleton. BioEssays. 1989; 10: 104-8.
75. Trimmer C, Whitaker-Menezes D, Bonuccelli G, et al. CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res. 2010; 70: 7489-99.
76. Navarro A, Anand-Apte B, Parat MO. A role for caveolae in cell migration. FASEB J. 2004; 18: 1801-11.
77. Han F, Zhu HG. Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res. 2010; 159: 443-50.
78. Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer. 1998; 82: 642-50.
79. Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004; 279: 51630-46.
80. Kim HN, Chung HS. Caveolin-1 inhibits membrane-type 1 matrix metalloproteinase activity. BMB Rep. 2008; 41: 858-62.
81. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell. 2004; 15: 4043-50.
82. Du ZM, Hu CF, Shao Q, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009; 125: 1832-41.
83. Niessen CM, Gottardi CJ. Molecular components of the adherens junction. Biochim Biophys Acta. 2008; 1778: 562-71.
84. Vasioukhin V, Bauer C, Degenstein L, et al. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell. 2001; 104: 605-17.
85. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27: 6920-9.
86. Imamichi Y, Menke A. Signaling pathways involved in collagen-induced disruption of the E-cadherin complex during epithelial-mesenchymal transition. Cells Tissues Organs. 2007; 185: 180-90.
87. Hu J, Shao S, Song Y, et al. Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec. 2010; 293: 1134-9.
88. Salem AF, Bonuccelli G, Bevilacqua G, et al. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle. 2011; 10: 3692-700.
89. Masuelli L, Budillon A, Marzocchella L, et al. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 2011; 227: 3344-53.
90. Yamaguchi H, Takeo Y, Yoshida S, et al. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res. 2009; 69: 8594-602.
91. Caldieri G, Giacchetti G, Beznoussenko G, et al. Invadopodia biogenesis is regulated by caveolin-mediated modulation of membrane cholesterol levels. J Cell Mol Med. 2009; 13: 1728-40.
92. Rizzo V, McIntosh DP, Oh P, et al. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem. 1998; 273: 34724-9.
93. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog. 2006; 5: 14.
94. Liu J, Wang XB, Park DS, et al. Caveolin 1 expression enhances endothelial capillary tubule formation. J Biol Chem. 2002; 277: 10661-8.
95. Griffoni C, Spisni E, Santi S, et al. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 2000; 276: 756-61.
96. Podar K, Shringarpure R, Tai YT, et al. Caveolin -1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004; 64: 7500-6.
97. Zhang ZB, Cai L, Zheng SG, et al. Overexpression of caveolin-1 in hepatocellular carcinoma with metastatis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res. 2009; 15: 495-502.
98. Goetz JG, Minguet S, Navarro-Lérida I, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011; 146: 148-63.
99. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, et al. The autophagic tumor stroma model of cancer or "battery-operated tumor growth": a simple solution to the autophagy paradox. Cell Cycle. 2010; 9: 4297-306.
100. Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009; 174: 2023-34.
101. Witkiewicz AK, Dasgupta A, Nguyen KH, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther. 2009; 8: 1071-9.
102. Sloan EK, Ciocca DR, Pouliot N, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009; 174: 2035-43.
103. Qian N, Ueno T, Kawaguchi-Sakita N, et al. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci. 2011; 102: 1590-6.
104. Di Vizio D, Morello M, Sotgia F, et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009; 8: 2420-4.
105. Wu KN, Queenan M, Brody JR, et al. Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle. 2011; 10: 4250-5.
106. Sotgia F, Del Galdo F, Casimiro MC, et al. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol. 2009; 174: 746-61.
107. Sotgia F, Martinez-Outschoorn UE, Pavlides S, et al. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res. 2011; 13: 213.
108. Castello-Cros R, Bonuccelli G, Molchansky A, et al. Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle. 2011; 10: 2021-34.
109. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001; 293: 2449-52.
110. Yang G, Timme TL, Naruishi K, et al. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol. 2008; 84: 131-40.
111. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest. 2001; 108: 1553-61.
112. Park DS, Woodman SE, Schubert W, et al. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol. 2002; 160: 2207-17.
113. Cohen AW, Park DS, Woodman SE, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 2003; 284: C457-74.
114. Razani B, Combs TP, Wang XB, et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2002; 277: 8635-47.
115. Pilch PF, Liu L. Fat caves: caveolae, lipid trafficking and lipid metabolism in adipocytes. Trends Endocrinol Metab. 2011; 22: 318-24.
116. Capozza F, Trimmer C, Castello-Cros R, et al. Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: role of Cav1 in Shh heterotypic signaling and transendothelial migration. Cancer Res. 2012; 72: 2262-74.
117. Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003; 4: 31-9.
118. Schmitz M, Zerr I, Althaus HH. Effect of cavtratin, a caveolin-1 scaffolding domain peptide, on oligodendroglial signaling cascades. Cell Mol Neurobiol. 2011; 31: 991-7.
119. Guarnieri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Exp Opin Pharmacother. 2012; 13: 395-406.
120. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem. 1998; 273: 32380-3.
121. Park J, Bae E, Lee C, et al. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumor Biol. 2010; 31: 643-50.
122. Conrad PA, Smart EJ, Ying YS, et al. Caveolin cycles between plasma membrane caveolae and the Golgi complex by microtubule-dependent and microtubule-independent steps. J Cell Biol. 1995; 131: 1421-33.
123. Yang CP, Galbiati F, Volonte D, et al. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 1998; 439: 368-72.
124. Hehlgans S, Eke I, Storch K, et al. Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. Radiother Oncol. 2009; 92: 362-70.
125. Ho CC, Kuo SH, Huang PH, et al. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008; 59: 105-10.
126. Dittmann K, Mayer C, Kehlbach R, et al. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 2008; 7: 69.
127. Cordes N, Frick S, Brunner TB, et al. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene. 2007; 26: 6851-62.
128. Li J, Hassan GS, Williams TM, et al. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle. 2005; 4: 1817-25.
129. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011; 2011: 842849.
130. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol. 2011; 33: 441-54.
131. Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci. 2004; 117: 5343-51.
132. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE. 2009; 4: e5219.